

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/525,998	03/15/2000	Rudolph Hauptmann	98.385-E	1361	
20306	7590 01/28/2005		EXAMINER		
MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP 300 S. WACKER DRIVE			O HARA, I	O HARA, EILEEN B	
	32ND FLOOR		ART UNIT	PAPER NUMBER	
CHICAGO,	L 60606		1646		

DATE MAILED: 01/28/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
Office Action Summary		09/525,998	HAUPTMANN ET AL.			
		Examiner	Art Unit			
		Eileen O'Hara	1646			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
THE - Exte after - If the - If NO - Failt Any	ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. nsions of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication, e period for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period we tree to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be within the statutory minimum of thirty (30) will apply and will expire SIX (6) MONTHS for cause the application to become ABANDO	timely filed days will be considered timely. om the mailing date of this communication. NED (35 U.S.C. § 133).			
Status						
1)🛛)⊠ Responsive to communication(s) filed on <u>5 November 2005</u> .					
2a) <u></u> ☐	This action is FINAL . 2b)⊠ This	action is non-final.				
3)□	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposit	ion of Claims					
4)⊠ 5)□	4) Claim(s) See Continuation Sheet is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) See Continuation Sheet is/are rejected. 7) Claim(s) is/are objected to.					
Applicat	ion Papers	٥				
9)[The specification is objected to by the Examiner	r.				
10)	10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.					
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
11)	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority ι	ınder 35 U.S.C. § 119					
12)⊠ a)∣	Acknowledgment is made of a claim for foreign All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prioric application from the International Bureau See the attached detailed Office action for a list of	s have been received. s have been received in Applicative documents have been received (PCT Rule 17.2(a)).	ation No. <u>07/511,430</u> . ived in this National Stage			
Attachmen	t(s)					
2) 🔲 Notic 3) 🔲 Inforr	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) r No(s)/Mail Date	4) Interview Summa Paper No(s)/Mail 5) Notice of Informa 6) Other:				

Continuation Sheet (PTOL-326)

Continuation of Disposition of Claims: Claims pending in the application are 27,49,64,67,68,71-74,76,77,79,81-86,89-91,94,96,97,102,104,105,110,111,114-116,119,121-123,126,128-135,138,139,144-168,170,172 and 174-178.

Continuation of Disposition of Claims: Claims rejected are 27,49,64,67,68,71-74,76,77,79,81-86,89-91,94,96,97,102,104,105,110,111,114-116,119,121-123,126,128-135,138,139,144-168,170,172 and 174-178.

Application/Control Number: 09/525,998 Page 2

Art Unit: 1646

DETAILED ACTION

Claims Status

1. Claims 27, 49, 64, 67, 68, 71-74, 76, 77, 79, 81-86, 89-91, 94, 96, 97, 102, 104, 105, 110, 111, 114-116, 119, 121-123, 126, 128-135, 138, 139, 144-168, 170, 172 and 174-178 are pending in the instant application.

Withdrawn Rejections

2. The rejection of claims under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-63 of U.S. Patent No. 6,294,352 is withdrawn in view of Applicants' terminal disclaimer filed Nov. 5, 2004.

Double Patenting

3. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 27, 49, 64, 67, 68, 71-74, 76, 77, 79, 81-86, 89-91, 94, 96, 97, 102, 104, 105, 110, 111, 114-116, 119, 121-123, 126, 128-135, 138, 139, 144-168, 170, 172 and 174-178 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable

Application/Control Number: 09/525,998

Art Unit: 1646

over claims 1-63 of U.S. Patent No. 6,440,693. Although the conflicting claims are not identical, they are not patentably distinct from each other because they are drawn to nucleic acids encoding polypeptides that are truncations/deletions of the full length TNF receptor polypeptide shown in SEQ ID NO: 2 that retain TNF binding activity (Figure 9 in both application and patent). The truncations/deletions are obvious because the skilled artisan would want to determine and use polypeptides that retain TNF binding activity but may be smaller than the full length polypeptide or other larger truncations.

Conclusion

4. No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Eileen B. O'Hara, whose telephone number is (571) 272-0878.

The examiner can normally be reached on Monday through Friday from 10:00 AM to 6:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa can be reached at (571) 272-0829.

The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (571) 272-1600.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

Application/Control Number: 09/525,998

Art Unit: 1646

Page 4

applications is available through Private PAIR only. For more information about the PAIR system, see http://portal.uspto.gov/external/portal/pair. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll free). Elea B.O'Hara

Eileen B. O'Hara, Ph.D.

Patent Examiner